Molecular pathology as the driving force for personalized oncology

Expert Review of Molecular Diagnostics

Volumn 12, Issue 8, 2012, Pages 811-813

  Oktay, Maja H ^a   Hui, Pei ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

molecular testing; personalized oncology

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; PROTEIN KINASE B;

ALGORITHM; BREAST CANCER; CANCER DIAGNOSIS; CHEMOSENSITIVITY; CLINICAL PRACTICE; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; CYTOLOGY; DRUG SENSITIVITY; EXOME; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC SCREENING; GENOTYPE; IMMUNOHISTOCHEMISTRY; LUNG CANCER; METASTASIS; MOLECULAR DIAGNOSIS; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; ONCOGENE N RAS; ONCOLOGY; PERSONALIZED MEDICINE; PHENOTYPE; PREDICTIVE VALUE; RISK ASSESSMENT; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; VALIDATION STUDY;

ANTINEOPLASTIC AGENTS; CYTOLOGICAL TECHNIQUES; EXOME; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; INDIVIDUALIZED MEDICINE; NEOPLASMS; PATHOLOGY, MOLECULAR; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84871278946     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.12.121     Document Type: Conference Paper

References (13)

1. Ziai J, Hui P. BRAF mutation testing in clinical practice. Expert Rev. Mol. Diagn. 12(2), 127-138 (2012).
2. Su Z, Dias-Santagata D, Duke M et al. A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. J. Mol. Diagn. 13(1), 74-84 (2011).
3. Lovly CM, Dahlman KB, Fohn LE et al. Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS ONE 7(4), e35309 (2012).
4. Robinson BD, Jones JG. Tumor microenvironment of metastasis (TMEM): a novel tissue-based assay for metastatic risk in breast cancer. Future Oncol. 5(7), 919-921 (2009).
5. Roussos ET, Goswami S, Balsamo M et al. Mena invasive (Mena(INV)) and Mena11a isoforms play distinct roles in breast cancer cell cohesion and association with TMEM. Clin. Exp. Metastasis 28(6), 515-527 (2011).
6. Oktay MH, Gertler FB, Liu YF, Rohan TE, Condeelis JS, Jones JG. Correlated immunohistochemical and cytological assays for the prediction of hematogenous dissemination of breast cancer. J. Histochem. Cytochem. 60(3), 168-173 (2012).
7. Smith SC, Baras AS, Lee JK, Theodorescu D. The COXEN principle: translating signatures of in vitro chemosensitivity into tools for clinical outcome prediction and drug discovery in cancer. Cancer Res. 70(5), 1753-1758 (2010).
8. Ferriss JS, Kim Y, Duska L et al. Multi-gene expression predictors of single drug responses to adjuvant chemotherapy in ovarian carcinoma: predicting platinum resistance. PLoS ONE 7(2), e30550 (2012).
9. Hewitt SM, Badve SS, True LD. Impact of preanalytic factors on the design and application of integral biomarkers for directing patient therapy. Clin. Cancer Res. 18(6), 1524-1530 (2012).
10. Ohashi K, Sequist LV, Arcila ME et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc. Natl Acad. Sci. USA 109(31), E2127-E2133 (2012).
11. Arcila ME, Chaft JE, Nafa K et al. prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin. Cancer Res. 18(18), 4910-4918 (2012).
12. Rekhtman N, Paik PK, Arcila ME et al. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin. Cancer Res. 18(4), 1167-1176 (2012)
13. 'My Cancer Genome' personalized cancer decision support tool. www.mycancergenome.org